- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Von Hippel-Lindau (VHL) disease
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 2.2MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 1.8MB)
Belzutifan – July 2024
Belzutifan; Tablet 40 mg; Welireg®
Last updated
30 May 2025